FDA Delays Decision on Amarin's Vascepa Drug

The plot deepens regarding the biotech company Amarin (NASDAQ: AMRN ) and its controversial cholesterol-controlling drug, Vascepa. As previously reported on Benzinga, Amarin was waiting to hear the results of a Food and Drug Administration ruling. The company had appealed the